跳到主要内容

LED Medical Diagnostics'子公司Apteryx,Inc。宣布为其XVWeb云成像服务提供新的3D模块的FDA批准

  • 2018年12月06日
  • 新闻发布

Vancouver,BC - 2018年12月6日 -LED Medical Diagnostics Inc.(“LED Medical”或“公司”)子公司Apteryx,Inc。(“Apteryx”)今天宣布他们的XVWeb 3D成像服务已获得美国食品和药物管理局的批准。XVWeb 3D独特地设计为通过为CBCT DICOM数据集提供具有各种可视化和诊断功能,通过直观的基于Web的用户界面为其XVWeb服务平台提供额外的功能。

XVWeb是牙科的领先图像归档和通信系统(PACS),提供最先进的临床图像捕获,可视化,分析和备份作为具有成本效益的订阅服务。XVWeb用户可以每天24小时访问其临床图像数据的整数,从兼容的网页连接设备7天。XVWeb 3D模块为患者CBCT图像数据增加了相同的可访问性和安全性。通过云处理和执行包括3D图像渲染的所有CBCT可视化,并通过全方位的图像分析和注释工具进行称赞。此外,XVWeb 3D为医疗保健提供者之间的患者图像共享提供了高效的过程,大大提高了与基于前提的软件系统相比的案例协作的效率。

“我们对云计算利用的影响令人兴奋,并将对综合形象采集,图像管理和治疗规划,凯文·克拉克斯(Apteryx),Inc。“Our team has developed a unique CBCT SaaS solution that gives clinicians the 3D treatment planning and visualization tools they need for more complex cases in a cloud environment, all while maintaining the exceptional image quality and handling that the industry has come to expect from Apteryx products.”

“XVWEB 3D从根本上改变了临床医生与CBCT数据集的方式进行了改变,”LED医疗首席执行官David Gane博士结束。“能够有效和安全地可视化和分享这些大数据集,而无需下载就会提供前所未有的改进工作流程灵活性和效率,这应该具有广泛的市场上诉。”

Apteryx基于Akron,Apteryx为牙科实践和许多大型牙科组织提供成像解决方案,包括美国军事,政府公共卫生诊所以及全国许多最大的牙科支持组织。金宝搏188bet官方网站了解有关Apteryx的更多信息,请访问www.aptyx.com.。对于XVWeb 3D的在线演示,请访问www.www.cultureversy.com/xvweb3d.

关于LED Medical Diagnostics Inc.

LED Medical Diagnostics Inc.是一家专注于提供最先进的成像软件和系统的牙科成像技术提供商。通过其全资子公司LED牙科Inc.,LED牙科有限公司和APTERYX,Inc。,LED医疗为牙医和口腔健康专家提供了高级诊断成像产品和软件20多年。金博188BETappios下载LED的专有技术包括Velscope VX增强的口腔评估和Tuxedo口内传感器,除了Apteryx的XRAYVision,XVWeb和XRayVision DCV成像软件解决方案之外还提供。

由经验丰富的领导团队支持,致力于更高的服务和支持,LED致力于为牙科从业人员提供最佳技术,通过识别和添加领先产品,以其越来越多的产品组合。金博188BETappios下载金宝搏188bet官方网站该公司目前在符号LMD下的TSX-V下列出,符号LEDIF下的OTCQB,以及符号LME下的法兰克福证券交易所。

媒体联系方式:

LED牙科
克里斯科赫
电话:678.293.9413
电子邮件:chris.koch@leddental.com.

公司联系人:

LED医疗
大卫盖内,首席执行官
电话:604.434.4614 x227
电子邮件:david.gane@leddent.com.

TSX Venture Exchange也没有其调节服务提供商(因为在TSX Venture交易所的政策中定义了该术语)接受此版本的充分性或准确性的责任

前瞻性陈述

本新闻稿包含陈述,即他们不是历史事实的重新结转的程度,可能构成根据适用的加拿大证券立法,涉及风险和不确定性的正面信息。Such forward-looking statements or information include statements regarding, but not limited to the Company’s future growth strategy, its distribution strategy and product offerings, potential expansion of the Company’s technology to other medical applications or markets, or the potential introduction of new technologies by the Company. Persons reading this press release are cautioned that such statements or information are only predictions, and that the Corporation’s actual future results or performance may be materially different. Factors that could cause actual events or results to differ materially from those suggested by these forward-looking statements include, but are not limited to competition risks, distributor risks, product development risks such as regulatory, design, intellectual property and other factors described in the Corporation’s reports filed on SEDAR including its Annual Information Form and financial report for the year ended December 31, 2017. These and other factors should be considered carefully and readers should not place undue reliance on such forward-looking information. All forward-looking statements made in this press release are qualified by this cautionary statement and there can be no assurance that actual results or developments anticipated by the Company will be realized. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.